StockData
Roivant Sciences Ltd. logo

Roivant Sciences Ltd. (ROIV) stock

ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.71+0.10 (+0.26%)

Close on Nov 17, 2026Market cap $27.96BP/E –Yield –

Roivant Sciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Roivant Sciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$816.47M. For fiscal 2025 it was -$750.35M. The highest annual figure on record is -$552.14M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Mar 31, 2026-$750.35M–
FY2024Mar 31, 2025-$839.45M–
FY2023Mar 31, 2024-$765.27M–
FY2022Mar 31, 2023-$843.39M–
FY2021Mar 31, 2022-$677.73M–
FY2020Mar 31, 2021-$552.14M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2026CQ2 2026Jun 30, 2026-$270.50M–
Q4 FY2025CQ1 2026Mar 31, 2026-$163.82M–
Q3 FY2025CQ4 2025Dec 31, 2025-$196.48M–
Q2 FY2025CQ3 2025Sep 30, 2025-$185.66M–
Q1 FY2025CQ2 2025Jun 30, 2025-$204.38M–
Q4 FY2024CQ1 2025Mar 31, 2025-$172.57M–
Q3 FY2024CQ4 2024Dec 31, 2024-$207.25M–
Q2 FY2024CQ3 2024Sep 30, 2024-$266.81M–
Q1 FY2024CQ2 2024Jun 30, 2024-$192.83M–
Q4 FY2023CQ1 2024Mar 31, 2024-$108.46M–
Q3 FY2023CQ4 2023Dec 31, 2023-$210.45M–
Q2 FY2023CQ3 2023Sep 30, 2023-$196.43M–
Q1 FY2023CQ2 2023Jun 30, 2023-$249.93M–
Q4 FY2022CQ1 2023Mar 31, 2023-$179.09M–
Q3 FY2022CQ4 2022Dec 31, 2022-$222.59M–
Q2 FY2022CQ3 2022Sep 30, 2022-$189.63M–
Q1 FY2022CQ2 2022Jun 30, 2022-$252.08M–
Q4 FY2021CQ1 2022Mar 31, 2022-$147.47M–
Q3 FY2021CQ4 2021Dec 31, 2021-$268.49M–
Q2 FY2021CQ3 2021Sep 30, 2021-$120.60M–
Q1 FY2021CQ2 2021Jun 30, 2021-$141.17M–
Q4 FY2020CQ1 2021Mar 31, 2021-$106.07M–
Q3 FY2020CQ4 2020Dec 31, 2020-$236.86M–
Q2 FY2020CQ3 2020Sep 30, 2020-$98.05M–
Q1 FY2020CQ2 2020Jun 30, 2020-$111.17M–

More Roivant Sciences figures

See a number that looks wrong?